ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,600 GBX | +0.35% |
|
+2.06% | +18.87% |
| 03:46pm | ASTRAZENECA : Berenberg raises its price target | CF |
| 01:58pm | AstraZeneca shares outperform, Berenberg raises target | CF |
| Sales 2024 * | 51.62B 71.13B | Sales 2025 * | 55.5B 76.48B | Capitalization | 248B 341B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.84B 12.19B | Net income 2025 * | 10.38B 14.3B | EV / Sales 2024 * | 5.19 x |
| Net Debt 2024 * | 20.42B 28.14B | Net Debt 2025 * | 13.72B 18.9B | EV / Sales 2025 * | 4.71 x |
| P/E ratio 2024 * |
28.2
x | P/E ratio 2025 * |
24
x | Employees | 89,900 |
| Yield 2024 * |
1.93% | Yield 2025 * |
2.03% | Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +0.53% | ||
| 1 week | +2.06% | ||
| Current month | +3.36% | ||
| 1 month | +1.86% | ||
| 3 months | +20.57% | ||
| 6 months | +24.80% | ||
| Current year | +18.87% |
1 week
12 322.00
12 704.00
1 month
11 858.0012 704.00
Current year
9 461.0012 704.00
1 year
9 461.0012 704.00
3 years
8 029.0012 704.00
5 years
5 871.0012 704.00
10 years
3 680.0012 704.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Director/Board Member | 68 | 99-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 218 M€ | +17.69% | ||
| 5.17% | 21 M€ | +7.83% | - | |
| 4.89% | 801 M€ | +12.02% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 12,600 | +0.35% | 1 115 469 |
| 24-06-07 | 12,556 | -0.27% | 2,907,425 |
| 24-06-06 | 12,590 | +0.59% | 1,326,464 |
| 24-06-05 | 12,516 | +0.90% | 1,815,207 |
| 24-06-04 | 12,404 | +0.47% | 1,646,266 |
Delayed Quote London S.E., June 10, 2024 at 09:51 am
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.87% | 248B | |
| +46.85% | 765B | |
| -6.48% | 354B | |
| +20.07% | 331B | |
| +9.07% | 299B | |
| -1.76% | 219B | |
| +10.91% | 216B | |
| +5.01% | 164B | |
| -3.00% | 162B | |
| +0.27% | 123B |
- Stock Market
- Equities
- AZN Stock
